Breaking News: Development Just In! Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI Jackson Center, PA September 11, 2024 – Halberd Corporation (OTC-PINK: "HALB”), in coordination with Athena Telemedicine Partners (ATP), and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with ...
Early Pilot Study Data from Veteran Volunteers is Compelling. Part B. Jackson Center, PA September 5, 2024 – Halberd Corporation (OTC-PINK: "HALB”) We hope you have had an opportunity to check out this Press release’s Part A. This Part B supplements that release of a few days ago. As always reach out to us if ...
Early Pilot Study Data from Veteran Volunteers is Compelling. Jackson Center, PA September 4, 2024 – Halberd Corporation (OTC-PINK: "HALB”) To our shareholders. As promised, this is the second of three Press Releases on our recent progress. If you have not had a chance to review that last one, on the good news on our ...
Jackson Center, PA July 24, 2024 – Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-AxTM nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. Dr. Russell Carr, the project's Principal Investigator, commented, “In the early ...
Walt Disney once said, “All our dreams can come true if we have the courage to pursue them”. Jackson Center, PA May 22, 2024 – Halberd Corporation (OTC-PINK: "HALB”) in cooperation with Athena GTX, Inc is standing at the threshold of some major advancements to treat the issues facing not only our military but people ...
Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously. Jackson Center, PA, May 9, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) two active programs for the treatment and mitigation of the negative effects of traumatic brain injury (TBI) align well with the newly passed bill in ...
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation Jackson Center, PA, April 30, 2024 – Halberd Corporation (OTC-PINK: "HALB”) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot ...
Jackson Center, PA, April 4, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd Corporation's patented drug, LDN+, a combination of low-dose Naltrexone and Cyclobenzaprine, is a central part of a just ...
Jackson Center, PA February 8, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and Use Committee. Dr. Russell Carr, the Primary Investigator, initiated preparations for this extension of the successful Phase #1 pilot test program, completed ...
Jackson Center, PA, January 11, 2024 -- Halberd Corporation (OTC: HALB) made significant advances in its technology development and accomplished major business goals during the second half of 2023. 2023 ACHIEVEMENTS Halberd received from the CDC two sets of antibiotic resistant bacteria and fungi (a total of 60 samples) on which to test its proprietary ...